GnRH Agonists and Antagonists Drugs for Endometriosis Market - 2024-2031

Report Overview

The Global GnRH agonists and antagonists drugs for endometriosis market reached US$ 861.25 million in 2023 and is expected to reach US$ 2,079.94 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.

Gonadotropin hormone-releasing hormone (GnRH) is the key regulator of the reproductive axis. Its pulsatile secretion determines the pattern of secretion of the gonadotropins follicle-stimulating hormone and luteinizing hormone, which then regulate both the endocrine function and gamete maturation in the gonads. Gonadotropin-releasing hormone (GnRH) agonists are synthetic substances that prevent the ovaries and testicles from producing sex hormones.

They work by blocking other hormones that are required for sex hormone production. Gonadotropin-releasing hormone (GnRH) antagonists are a class of drugs that block the pituitary gland from producing hormones like follicle-stimulating hormone (FSH) and luteinizing hormone (LH). GnRH agonists work by down-regulating the hypothalamic-pituitary-gonadal axis, ultimately leading to suppression of ovulation and reduced estrogen levels, a key hormone known to stimulate endometriosis.

Market Dynamics: Drivers

Increasing prevalence of endometriosis

The rising prevalence of endometriosis propels the market growth. For instance, according to an article posted by WHO in March 2023, endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. There is currently no known cure for endometriosis and treatment is usually aimed at controlling symptoms. Access to early diagnosis and effective treatment of endometriosis is important but is limited in many settings, including in low- and middle-income countries.

Moreover, according to Endometriosis UK, 1 in 10 women and those assigned female of birth of reproductive age in the UK suffer from endometriosis. 10% of women worldwide have endometriosis - that's 176 million worldwide. The prevalence of endometriosis in women with infertility can be as high as 30-50%. Endometriosis is the second most common gynecological condition in the UK. Endometriosis affects 1.5 million women and those assigned female at birth, a similar number of those affected by diabetes. On average it takes 8 years and 10 months from the first GP visit to get a diagnosis.

Restraints

Factors such as adverse effects and risks related to gonadotropin-releasing hormone agonists and antagonists are expected to hamper the market. In some cases, the usage of GnRH agonists and antagonists results in hot flashes, gynecomastia, fatigue, weight gain, fluid retention, erectile dysfunction, decreased libido, decrease in bone density, and irregular menstrual cycle.

Market Segment Analysis

The global GnRH agonists and antagonists drugs for endometriosis market is segmented based on drug type, end-user, and region.

The segment GnRH antagonists accounted for approximately 45.4% of the global GnRH agonists and antagonists drugs for endometriosis market share

The GnRH antagonists segment is expected to hold the largest market share over the forecast period. In this segment, the increasing demand would drive this market. Gonadotropin-releasing hormone (GnRH) antagonists are a promising treatment option for endometriosis and can help with pain relief and disease progression. GnRH antagonists reduce estrogen levels by downregulating the hypothalamic-pituitary-gonadal axis. This can help prevent disease progression and reduce the likelihood of endometriosis returning after surgery.

Oral GnRH antagonists, including elagolix, relugolix, and linzagolix allow oral administration, induce the dose-dependent reduction of estradiol levels, do not cause initial flare-up of endometriosis symptoms, and allow the fast return of ovarian function and menstruation after discontinuation. GnRH antagonists demand is increasing day by day due to advantages such as shorter treatment time, lower risk of ovarian hyperstimulation syndrome, less consumption of FSH, and improved patient acceptance.

Market Geographical Analysis

North America accounted for approximately 43.2% of the global GnRH agonists and antagonists drugs for endometriosis market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of endometriosis, and growing awareness among people, in this region, help to propel the market.

For instance, according to John Hopkins Medicine, endometriosis affects an estimated 2 to 10 percent of American women between the ages of 25 and 40. Endometriosis affects up to 10% of women between the ages of 15 and 44. It most often occurs on or around reproductive organs in the pelvis or abdomen. The American Society for Reproductive Medicine found that 24% to 50% of women with infertility have endometriosis. Mild to moderate cases of endometriosis may only cause temporary infertility. Researchers estimate that at least 11% of women in the United States have endometriosis, which is more than 6.5 million women.

Moreover, in August 2022, Pfizer and Myovant Sciences' MYFEMBREE(R) (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved by the U.S. Food and Drug Administration (FDA) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women, with a treatment duration of up to 24 months.

Market Segmentation

By Drug Type

GnRH Agonists

Leuprolide

Goserelin

Nafarelin

GnRH Antagonists

Elagolix

Relugolix

By End-User

Hospitals

Specialty Clinics

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global GnRH agonists and antagonists drugs for endometriosis market include Bayer AG, Ferring, Abbvie Inc., AstraZeneca, Merck KGaA, Ipsen Pharma, TerSera Therapeutics LLC, Takeda Pharmaceutical Company Limited, Cipla, Lupin among others.

Key Developments

In June 2023, the US Food and Drug Administration approved the use of leuprolide acetate in a depot preparation, goserelin implant, and intranasal nafarelin for up to six months when administered alone for the treatment of symptomatic endometriosis.

Why Purchase the Report?

To visualize the global GnRH agonists and antagonists drugs for endometriosis market segmentation based on drug type, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global GnRH agonists and antagonists drugs for endometriosis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global GnRH agonists and antagonists drugs for endometriosis market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies